XIAP expression correlates with monocytic differentiation in adult de novo AML: Impact on prognosis

Hematology Journal

Volumn 5, Issue 6, 2004, Pages 489-495

  Tamm, Ingo ^a,c   Richter, Stephan ^a   Scholz, Frank ^a   Schmelz, Karin ^a   Oltersdorf, Doreen ^a   Karawajew, Leonid ^a   Schoch, Claudia ^b   Haferlach, Torsten ^b   Ludwig, Wolf Dieter ^a   Wuchter, Christian ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d PAREXEL INTERNATIONAL   (United States)

Author keywords

AML; IAPs; Monocytic differentiation; Prognostic factors

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CD14 ANTIGEN; CD36 ANTIGEN; CD4 ANTIGEN; HLA DR ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS;

ADULT; AGED; ANTIGENS, DIFFERENTIATION; CASPASE 3; CASPASES; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMAGE CYTOMETRY; IMMUNOPHENOTYPING; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MONOCYTES; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SURVIVAL ANALYSIS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 19944419093     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200549     Document Type: Article

References (28)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncolocy. Lancet Oncol 2001; 2: 33-42.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization Classification of neoplastic diseases fo the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, VA, November, 1997. J Clin Oncol 1999; 10: 1419-1432.
5. Büchner T, Hiddemann W, Wörmann B. Intensive consolidation versus prolonged maintenance following intensive induction and conventional consolidation in primary AML: a study of the AMLCG. Blood 2001; 88: 214.
6. Kern W, Haferlach T, Schoch C, Löffler H, Gassmann W, Heinecke A et al. Early blast clearance by remissision induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group 1992 Trial. Blood 2003; 101: 64-70.
7. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
8. Wuchter C, Karawajew L, Ruppert V, Büchner T, Schoch C, Haferlach T et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13: 1943-1953.
9. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
10. Schoch C, Haferlach T, Haase D, Fonatsch C, Löffler H, Schlegelberger B et al. German AML Cooperative Study Group. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118-126.
11. Kaplan EL. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-460.
12. Andreeff M, Jiang S, Zhang X. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoid acid. Leukemia 1999; 13: 1881-1892.
13. Miranda MB, Dyer KF, Grandis JR, Johnson DE. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-XL and XIAP in the prolonged survival of monocytic cells. Leukemia 2003; 17: 390-400.
14. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998; 188: 211-216.
15. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. Increased IkB kinase activity is associated with activated NF-kB in acute myeloid leukemia. Leukemia 2002; 16: 2062-2071.
16. Wood KM, Roff M, Hay RT. Defective IkB alpha in Hodgkin cell lines with constitutively active NF-kB. Oncogene 1998; 16: 2131-2139.
17. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-kB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953.
18. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dörken B et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001; 15: 921-928.
19. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
20. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
21. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998; 273: 7787-7790.
22. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M et al. Caspase-independent cell death in AML: caspase-inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003; 58: 5315-5320.
23. Adida C, Berrebi D, Peuchmaur M. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351: 882-883.
24. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812.
25. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of surviving in myeloid leukemia. Blood 2001; 97: 2784-2790.
26. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196-203.
27. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M et al. Identification of c-IAP1 as a candidate target gene within an amplicon at 11q22 in oesophageal squamous cell carcinoma. Cancer Res 2001; 61: 6629-6634.
28. Svingen PA, Karp JE, Krajewski S, Mesner Jr PW, Gore SD, Burke PJ et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 2000; 96: 3922-3931.